Status: Recruiting
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Participants needed: 120
Trial details
Phase: Phase 2Age: 5-20Biological sex: AllType: InterventionalSponsor: Mohsen SaidinejadUpdated: Mar 9, 2026Locations: 1
Eligibility criteria
Between the ages 5-20 years [+5]
Sickle cell trait only [+16]